

Close of Non-Renounceable Rights Issue

28 August 2020, Melbourne: Rhythm Biosciences Limited (ASX: RHY or "Rhythm") advises that its 3 for 5 Non-Renounceable Rights Issue closed at 5:00pm (AEST) on 28 August 2020.

As announced to the ASX on 23 July 2020, Rhythm conducted a capital raising by way of a Non-Renounceable Rights Issue (Entitlement Offer) to shareholders which had a record date of 28 July 2020, on the basis of three (3) new fully paid ordinary share (Share) for every five (5) existing Shares held at an issue price of \$0.6 (6 cents) per new Share (before costs).

The funds raised by the Entitlement Offer will be used by the Company as set out in the Non-renounceable rights issue Offer document released to the ASX on 31 July 2020.

Once all applications are received and audited, Rhythm will notify the ASX of any undersubscriptions and in accordance with the offer, any Shortfall Shares will be allocated and issued pursuant to the terms set out in the Entitlement Offer announced on 31 July 2020.

Released with the authority of the Board.



Adrien Wing
Company Secretary

About Rhythm Biosciences

ASX-listed Rhythm Biosciences is endeavoring to develop and commercialise a screening and diagnostic test for the early detection of colorectal cancer, the third biggest cause of cancer-related deaths globally.

Rhythm's lead product, ColoSTAT[®], is intended to be a simple, affordable, minimally invasive and effective blood test for the early detection of bowel cancer for the global mass market. It is expected to be comparable to, if not better than, the current standard of care, the faecal immunochemical test (FIT), at a lower cost. ColoSTAT[®] also provides an alternative for those who choose not to, or are unable to, be assessed using standard screening programs.

ColoSTAT[®] is designed to be used easily by laboratories without the need for additional operator training or additional infrastructure.

ColoSTAT[®] has the potential to play an important role in reducing the morbidity and mortality rates and healthcare costs associated with colorectal cancer. Globally, over 850,000 people die from colorectal cancer each year.

Rhythm Biosciences

ACN: 619 459 335
ASX: RHY

Issued Capital

115,862,000 Shares
3,000,000 Options

Australian Registered Office

Level 2, 480 Collins Street
Melbourne VIC 3000
www.rhythmbio.com

Directors

Otto Buttula – Chairman of the Board
Trevor John Lockett – Executive Director
Louis James Panaccio – Non-Executive Director
David John White – Non-Executive Director
Eduardo Vom – Non-Executive Director